Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.42 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | VSIR | Q9H7M9 | 3/20 | 0.38 |
| ▸ | TARS1 | P26639 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5579160 | 1.00 | MME (0.43) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL7218621 | 1.00 | MME (0.43) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL27663801 | 1.00 | MME (0.43) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL5579158 | 1.00 | MME (0.43) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL10803670 | 1.00 | MME (0.43) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL31174304 | 1.00 | MME (0.43) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL5495971 | 0.96 | MME (0.41) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL5495978 | 0.96 | MME (0.41) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL19734968 | 0.96 | MME (0.41) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL30011012 | 0.96 | MME (0.41) | MMECD274PDCD1LG2CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| EP-4735021-A1 | COMBINATION THERAPY | Zealand Pharma A/S (DK) | 2026-05-06 | — | — | EP | claimed |
| EP-4731239-A1 | ANALOGUES WITH IMPROVED PROPERTIES | Zealand Pharma A/S (DK) | 2026-04-29 | — | — | EP | claimed |
| EP-4074729-B1 | AMYLIN ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-04-15 | — | — | EP | claimed |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2026-01-29 | — | — | US | claimed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| WO-2025149667-A1 | ANTIBODY DRUG CONJUGATES AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2025-07-17 | — | — | WO | claimed |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | US | claimed |
| WO-2025120085-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | WO | claimed |
| EP-4554623-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | Pheon Therapeutics Ltd (GB) | 2025-05-21 | — | — | EP | claimed |
| WO-2024013724-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2024-01-18 | — | — | WO | claimed |
| WO-2024013723-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2024-01-18 | — | — | WO | claimed |
| WO-2023049852-A1 | ADENOVIRUSES AND METHODS FOR USING ADENOVIRUSES | SAGITTARIUS BIO, INC. (US) | 2023-03-30 | — | — | WO | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| EP-4144362-A1 | COMPOSITIONS COMPRISING SHORT-ACTING HORMONES FOR TREATING OR PREVENTING OBESITY AND PUMPS COMPRISING SAID COMPOSITION | Adocia (FR) | 2023-03-08 | — | — | EP | claimed |
| EP-4129324-A1 | COMPOSITIONS COMPRISING AT LEAST AN AMYLIN RECEPTOR AGONIST AND A GLP-1 RECEPTOR AGONIST | Adocia (FR) | 2023-02-08 | — | — | EP | claimed |
| EP-4074729-A1 | AMYLIN ANALOGUES | Zealand Pharma A/S (DK) | 2022-10-19 | — | — | EP | claimed |
| CN-115047120-A | Dansyl chloride derivatization method for analyzing and detecting dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2022-09-13 | — | — | CN | claimed |
| US-11382956-B2 | Amylin analogues | ZEALAND PHARMA A/S (DK) | 2022-07-12 | — | — | US | claimed |
| CN-113956348-A | Glucagon and GLP-1 co-agonist compounds | 伊莱利利公司 | 2022-01-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | BCR, TBCD, TBC1D5 | MME 3409/4885CD274 151/4885PDCD1LG2 37/4885 |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | MME 4355/4885CD274 289/4885PDCD1LG2 692/4885 |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | SLC3A2, MTCL3, SLC13A2 | MME 3897/4885CD274 102/4885PDCD1LG2 40/4885 |
| US-11382956-B2 | Amylin analogues | IAPP, GLP1R, AMY2A | MME 78/4885CD274 4415/4885PDCD1LG2 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.